Pasithea Therapeutics Statistics
Total Valuation
KTTA has a market cap or net worth of $18.16 million. The enterprise value is -$32.24 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KTTA has 33.41 million shares outstanding. The number of shares has increased by 804.92% in one year.
| Current Share Class | 33.41M |
| Shares Outstanding | 33.41M |
| Shares Change (YoY) | +804.92% |
| Shares Change (QoQ) | +90.58% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 14.96% |
| Float | 16.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.40
| Current Ratio | 35.40 |
| Quick Ratio | 33.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.22% and return on invested capital (ROIC) is -32.99%.
| Return on Equity (ROE) | -58.22% |
| Return on Assets (ROA) | -31.49% |
| Return on Invested Capital (ROIC) | -32.99% |
| Return on Capital Employed (ROCE) | -32.61% |
| Weighted Average Cost of Capital (WACC) | 5.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.95M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.89% in the last 52 weeks. The beta is 0.25, so KTTA's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -24.89% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.80 |
| Relative Strength Index (RSI) | 37.11 |
| Average Volume (20 Days) | 440,578 |
Short Selling Information
The latest short interest is 274,584, so 0.82% of the outstanding shares have been sold short.
| Short Interest | 274,584 |
| Short Previous Month | 297,457 |
| Short % of Shares Out | 0.82% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 0.65 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.89M |
| Pretax Income | -19.73M |
| Net Income | -19.73M |
| EBITDA | -17.23M |
| EBIT | -17.89M |
| Earnings Per Share (EPS) | -$1.57 |
Full Income StatementBalance Sheet
The company has $50.40 million in cash and n/a in debt, giving a net cash position of $50.40 million or $1.51 per share.
| Cash & Cash Equivalents | 50.40M |
| Total Debt | n/a |
| Net Cash | 50.40M |
| Net Cash Per Share | $1.51 |
| Equity (Book Value) | 54.81M |
| Book Value Per Share | 2.20 |
| Working Capital | 51.24M |
Full Balance SheetCash Flow
| Operating Cash Flow | -16.94M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 657,764 |
| Net Borrowing | 179,310 |
| Free Cash Flow | -16.94M |
| FCF Per Share | -$0.51 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |